Synonym
Pirazolac; ZK 76 604; Pirazolacum
IUPAC/Chemical Name
1H-Pyrazole-3-acetic acid, 4-(4-chlorophenyl)-1-(4-fluorophenyl)-
InChi Key
YAMFWQIVVMITPG-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H12ClFN2O2/c18-12-3-1-11(2-4-12)15-10-21(20-16(15)9-17(22)23)14-7-5-13(19)6-8-14/h1-8,10H,9H2,(H,22,23)
SMILES Code
O=C(O)CC1=NN(C2=CC=C(F)C=C2)C=C1C3=CC=C(Cl)C=C3
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
330.74
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Kurowski M, Dunky A, Geddawi M. Transsynovial distribution and protein binding of pirazolac in patients with rheumatoid arthritis. Eur J Clin Pharmacol. 1986;31(3):307-11. doi: 10.1007/BF00981129. PMID: 3792428.
2: Numo R. Multicentre double-blind study of the efficacy, safety and tolerance of pirazolac compared with sulindac in patients with rheumatoid arthritis. Drugs Exp Clin Res. 1990;16(1):17-27. PMID: 2198156.
3: Bown RL, Martin BK, Geddawi M. Comparison of occult blood loss caused by pirazolac and diclofenac sodium: a double-blind crossover study. Curr Med Res Opin. 1985;9(8):548-51. doi: 10.1185/03007998509109633. PMID: 3875451.
4: Turner RA, Johnson JA, Turner SR, McGee M, Kashanian F. Neutrophil functional and arachidonic acid metabolic correlates and clinical disease activity in pirazolac-treated rheumatoid arthritis patients. Drugs Exp Clin Res. 1990;16(1):39-48. PMID: 2115831.
5: Täuber U, Weiss C, Krause W, Acksteiner B, Matthes H. Pharmacokinetics of pirazolac--a new anti-inflammatory drug--in human volunteers. I. Absorption, disposition, biotransformation and excretion. Eur J Drug Metab Pharmacokinet. 1985 Jan-Mar;10(1):41-53. doi: 10.1007/BF03189696. PMID: 4029220.
6: Symmons D, Clark B, Panayi G, Geddawi M. Differential dosing study of pirazolac, a new non-steroidal anti-inflammatory agent, in patients with rheumatoid arthritis. Curr Med Res Opin. 1985;9(8):542-7. doi: 10.1185/03007998509109632. PMID: 3896664.
7: Carcassi C, La Nasa G, Perpignano G. A 12-week double-blind study of the efficacy, safety and tolerance of pirazolac b.i.d. compared with indomethacin t.i.d. in patients with ankylosing spondylitis. Drugs Exp Clin Res. 1990;16(1):29-37. PMID: 2198157.
8: Tavares IA, Bennett A. Effect of pirazolac on prostanoid synthesis by human gastric mucosa in vitro. Drugs Exp Clin Res. 1990;16(1):1-6. PMID: 2115830.
9: Täuber U, Weiss C, Matthes H. Pharmacokinetics of Pirazolac - a New Anti- Inflammatory Drug - in Human Volunteers II. Dose Linearity of Plasma Levels and Excretion. Pharm Res. 1985 Jul;2(4):188-91. doi: 10.1023/A:1016396224046. PMID: 24272813.
10: Kurowski M, Dunky A, Geddawi M. Effects of pirazolac on arachidonic acid metabolism in the human synovial system. Curr Med Res Opin. 1987;10(7):494-501. doi: 10.1185/03007998709112409. PMID: 3040340.
